Moderna Inc. Stock

Shares of vaccine stocks Moderna (NASDAQ: MRNA), Novavax (NASDAQ: NVAX), and BioNTech SE (NASDAQ: BNTX) rallied this week, appreciating 23.4%, 16.4%, and 9.3%, respectively, through Thursday

Moderna (NASDAQ: MRNA) isn't new to artificial intelligence (AI). The biotech best known for its billion-dollar coronavirus vaccine has been using this hot technology for years to help it save

Novavax (NASDAQ: NVAX) and Moderna (NASDAQ: MRNA) both entered the coronavirus vaccine race around the same time, in early pandemic days, and their shares soared -- in fact, Novavax rose the most

Investors have put their hopes in Moderna's (NASDAQ: MRNA) next potential product, a respiratory syncytial virus (RSV) vaccine. That's because it represents a new revenue stream for a company that

Equities have been on a bull run for well over a year. Though it might be tempting to invest in stocks that have largely been in tandem with the broader market, it's even better to consider those

Moderna (NASDAQ: MRNA) and OpenAI are collaborating to bring artificial intelligence (AI) to every level of the biotech's operations, and the implications could perhaps be significant for investors

Five years ago, pharmaceutical company Moderna (NASDAQ: MRNA) was mostly unknown. It was developing vaccines that induce human immune cells to more effectively fight disease. But the science of

Moderna (NASDAQ: MRNA) was a fine stock to heal an ailing portfolio on the second-to-last trading day of the week. The company, which developed and sells the Spikevax COVID-19 vaccine, saw its share

Image source: The Motley Fool.

Moderna (NASDAQ: MRNA)Q1 2024 Earnings CallMay 02, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Moderna (NASDAQ: MRNA) stock soared earlier in the pandemic as the company developed its coronavirus vaccine and the product went on to generate billions of dollars in sales. But as demand for the

According to some new data revealed by Moderna (NASDAQ: MRNA) at the American Association for Cancer Research Annual Meeting on April 8, the biotech responsible for the Spikevax coronavirus vaccine

For many, Moderna (NASDAQ: MRNA) stock is yesterday's news. The stock earned a great deal of attention during the coronavirus pandemic, as it was one of the early developers of a vaccine to fight

Before the COVID-19 pandemic, most investors likely hadn't heard of Moderna (NASDAQ: MRNA). At the end of 2019, it was a relatively small biotech company with only collaboration and grant revenue

Moderna (NASDAQ: MRNA) shot to stardom in the early days of the pandemic as it brought its coronavirus vaccine from drawing board to commercialization in less than a year -- and then went on to

It's always possible to come up with a justification for why someone should sell their shares of a stock, but that doesn't make every justification correct. For a company like Moderna (NASDAQ: MRNA)

Moderna (NASDAQ: MRNA) was a top stock to own during the early stages of the pandemic. The COVID-19 vaccine maker reached a market cap of nearly $200 billion at its peak in 2021. But nowadays, with

The past four years have been a roller-coaster ride for Moderna (NASDAQ: MRNA). The mRNA-focused vaccine maker rose to prominence following a successful attempt at developing a coronavirus vaccine.

You can find growth stocks in every sector. With healthcare making up nearly one-fifth of the U.S. economy, it's a great place to look.

Three Motley Fool contributors have identified what they think

Regarding Moderna (NASDAQ: MRNA) stock, RBC Capital analyst Luca Issi is bullish. Per his price target of $125 that he reiterated on Feb. 23, the biotech's shares could rise by 30% to reach $125

Image source: The Motley Fool.

Moderna (NASDAQ: MRNA)Q4 2023 Earnings CallFeb 22, 2024, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Shares of Moderna (NASDAQ: MRNA) were jumping 9.5% higher as of 11:09 a.m. ET on Thursday after rising as much as 10% earlier in the day. The gain came after the biotech company announced its

There's arguably no better time to buy a stock than when it's been beaten down. Doing so provides a reasonable entry point for investors willing to hold the stock for a while, which can translate to

Moderna (NASDAQ: MRNA) shares skyrocketed in the early stages of the pandemic as the biotech company became one of the first to bring a vaccine to market. That vaccine went on to generate billions

Growth stocks are supposed to, well, grow. That's especially the expectation when the overall stock market soars as it did in 2023.

However, even the best growth stocks can experience rough patches

Moderna (NASDAQ: MRNA) was one of the hottest stocks to own during the rollout of COVID-19 vaccines a few years ago. These days, however, the hype has cooled off significantly. The company is facing